What are the benefits of taking ACE inhibitors for patients with HFrEF?
ACE inhibitors reduce morbidity and mortality in heart failure with reduced ejection fraction (HFrEF). Randomized controlled trials (RCTs) have clearly established the benefits of ACE inhibition in patients with mild, moderate, or severe symptoms of HF, and in patients with or without coronary artery disease. ACE inhibitors can produce angioedema and should be given with caution to patients with low systemic blood pressures, renal insufficiency, or elevated serum potassium. Long-term therapy with ACE inhibitors has been shown to reduce morbidity and mortality, especially in ACE inhibitor intolerant patients.